Join
Live feed
·
PRReleasevia Quantisnow
Oculis Holding AG logo

Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease

ByQuantisnow·Wall Street's wire, on your screen.
OCS· Oculis Holding AG
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track OCS (Oculis Holding AG) and more on Quantisnow.